Hospital Clínic, Department of Medical Oncology, Barcelona, Spain.
Clin Transl Oncol. 2011 May;13(5):328-34. doi: 10.1007/s12094-011-0662-5.
The purpose of the Spanish Lung Cancer Anaemia Survey (SLCAS) was to thoroughly investigate lung cancer-associated anaemia management, and describe the profile of lung cancer patients in relation to anaemia incidence and tumour type in Spain.
This survey collected data from 1089 randomly recruited patients gathered by 50 Spanish physicians at 38 sites. In addition, a qualitative assay was performed through 16 one-to-one and 2 one-to-two interviews, and a discussion group of 4 cancer specialists participating in the survey.
Lung cancer patients undergoing chemotherapy treatment had haemoglobin (Hb) levels <12.0 g/dl in 58.0% of the cases, in contrast to 39.0% of patients receiving no chemotherapy. Anaemia was treated in 53.0% of patients with Hb<12 g/dl (45.0% epoetin, 3.9% transfusion, 4.1% iron). Mean Hb level trigger was 9.7 g/dl for administration of epoetin and 8.2 g/dl for blood transfusion.
SLCAS reveals a significant change in the management of anaemia and clinical practice pattern in the use of erythropoiesis-stimulating agents (45.0% vs. 18.0%) and much less use of blood transfusions (3.9% vs. 15.0%) since the European Cancer Anaemia Survey performed five years ago.
西班牙肺癌贫血调查（SLCAS）的目的是彻底调查肺癌相关贫血的管理，并描述与贫血发生率和肿瘤类型相关的肺癌患者的特征。
这项调查通过 50 名西班牙医生在 38 个地点随机招募了 1089 名患者，收集了数据。此外，还通过 16 次一对一和 2 次一对二访谈以及参与调查的 4 名癌症专家的讨论小组进行了定性分析。
接受化疗的肺癌患者中有 58.0%的血红蛋白（Hb）水平<12.0 g/dl，而未接受化疗的患者中有 39.0%。Hb<12 g/dl 的 53.0%患者接受了贫血治疗（45.0%使用促红细胞生成素，3.9%输血，4.1%补铁）。使用促红细胞生成素的平均 Hb 水平触发值为 9.7 g/dl，输血的触发值为 8.2 g/dl。
SLCAS 揭示了贫血管理以及使用红细胞生成刺激剂（45.0%对 18.0%）和输血（3.9%对 15.0%）的临床实践模式的显著变化，这是自五年前进行的欧洲癌症贫血调查以来发生的变化。
